Clay Siegall Purchases 62,500 Shares of Shattuck Labs (NASDAQ:STTK) Stock

Shattuck Labs, Inc. (NASDAQ:STTK) Director Clay Siegall bought 62,500 shares of Shattuck Labs stock in a transaction dated Tuesday, June 9th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $250,000.00. Following the purchase, the director directly owned 318,608 shares in the company, valued at $1,274,432. This represents a 24.40% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Shattuck Labs Stock Performance

Shares of NASDAQ:STTK traded up $0.05 on Thursday, hitting $4.18. The stock had a trading volume of 916,353 shares, compared to its average volume of 687,374. Shattuck Labs, Inc. has a twelve month low of $0.71 and a twelve month high of $8.33. The firm’s 50 day moving average price is $6.42 and its 200-day moving average price is $4.93. The company has a market capitalization of $320.53 million, a price-to-earnings ratio of -6.63 and a beta of 1.08.

Shattuck Labs (NASDAQ:STTK) last issued its earnings results on Thursday, May 7th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. During the same quarter last year, the company posted ($0.27) earnings per share. As a group, sell-side analysts predict that Shattuck Labs, Inc. will post -0.51 EPS for the current year.

Analysts Set New Price Targets

STTK has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $18.00 target price on shares of Shattuck Labs in a research note on Monday. Citigroup upgraded shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a research note on Friday, June 5th. Wedbush lifted their price target on Shattuck Labs from $8.00 to $11.00 and gave the company an “outperform” rating in a report on Friday, May 8th. Needham & Company LLC lifted their price target on Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. Nine analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Shattuck Labs presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. The Manufacturers Life Insurance Company raised its holdings in shares of Shattuck Labs by 5.4% in the first quarter. The Manufacturers Life Insurance Company now owns 142,300 shares of the company’s stock valued at $915,000 after buying an additional 7,244 shares during the last quarter. OMERS ADMINISTRATION Corp raised its holdings in Shattuck Labs by 25.7% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 33,300 shares of the company’s stock worth $214,000 after purchasing an additional 6,800 shares during the last quarter. Renaissance Technologies LLC raised its holdings in Shattuck Labs by 77.4% during the 1st quarter. Renaissance Technologies LLC now owns 604,500 shares of the company’s stock worth $3,887,000 after purchasing an additional 263,800 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in Shattuck Labs by 571.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 155,642 shares of the company’s stock worth $1,001,000 after purchasing an additional 132,450 shares during the last quarter. Finally, Hillsdale Investment Management Inc. bought a new stake in Shattuck Labs during the 1st quarter worth about $421,000. 58.74% of the stock is owned by institutional investors.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical?stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten?carrier conjugate technology designed to generate high?affinity drug?specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood?brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.